Leqvio for ASCVD Secondary Prevention: Off-Label Evidence Summary

What Is the FDA-Approved Indication for Inclisiran?

The FDA approved inclisiran on December 22, 2021 as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The approval was granted under the brand name Leqvio, manufactured by Novartis.

The phrase "established clinical ASCVD" in the label mirrors the ACC/AHA definition: prior acute coronary syndrome, myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. The FDA prescribing information does not specify a minimum baseline LDL-C threshold for the ASCVD subgroup, but the key trials enrolled patients with LDL-C of 70 mg/dL or higher despite statin therapy.

What Counts as "Off-Label" Use in This Context?

Off-label use arises when inclisiran is prescribed outside the conditions named in the label. Concrete examples include:

• Patients with ASCVD risk equivalents (e.g., diabetes with target organ damage, chronic kidney disease) who have not had a documented ASCVD event
• Patients not currently on a statin due to documented intolerance, where inclisiran is used as monotherapy
• Pediatric patients (the label covers adults only)
• Primary prevention in very-high-risk patients who have not yet experienced a clinical event

None of these scenarios have prospective randomized trial data specifically designed around them, which places the evidence base at a lower confidence level than the approved indication.

Regulatory Field Beyond the United States

The European Medicines Agency (EMA) approved inclisiran in December 2020 under the trade name Leqvio. The EMA label is somewhat broader: it covers primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or other lipid-lowering therapies. This means a European clinician prescribing inclisiran to a patient with non-familial hypercholesterolaemia and ASCVD may be acting within label, while a U.S. Clinician doing the same may be prescribing off-label. Understanding this difference matters when reviewing published prescribing patterns from European centers.

The ORION Trial Program: Core Evidence

The ORION clinical program comprises more than ten phase 2 and phase 3 trials. Three phase 3 studies most relevant to ASCVD secondary prevention are ORION-9, ORION-10, and ORION-11. A large cardiovascular outcomes trial, ORION-4, is ongoing.

ORION-9 (HeFH Population)

ORION-9 enrolled 482 adults with HeFH on maximally tolerated lipid-lowering therapy. At 510 days, inclisiran reduced LDL-C by 39.7% from baseline compared with placebo (P<0.001). Published in the New England Journal of Medicine, the trial demonstrated consistent LDL-C lowering across the every-6-month dosing schedule after the initial two doses.

ORION-10 and ORION-11 (Clinical ASCVD and High-Risk Populations)

ORION-10 enrolled 1,561 patients with ASCVD already on maximally tolerated statins. Inclisiran reduced LDL-C by 52.3% from baseline vs. Placebo at day 510 (P<0.001). ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents, including patients with diabetes and hypertension without a prior event, achieving a 49.9% LDL-C reduction at day 510 (P<0.001). Both trials were published together in the New England Journal of Medicine in 2020.

The ORION-11 design is particularly relevant to the off-label question. Approximately 30% of that cohort had ASCVD risk equivalents rather than established ASCVD events. Their LDL-C reductions were numerically similar to the established-ASCVD subgroup, though the trial was not powered to detect a difference between subgroups on surrogate endpoints, let alone hard outcomes.

Safety Across Phase 3 Trials

Pooled phase 3 data show injection-site reactions in approximately 4.7% of inclisiran-treated patients versus 0.5% for placebo, nearly all mild-to-moderate and resolving without intervention. Serious adverse events occurred at rates comparable to placebo. Liver transaminase elevations above three times the upper limit of normal were rare (<1%). There were no meaningful signals for myopathy, neurocognitive effects, or new-onset diabetes, which differentiates the PCSK9 siRNA class from some statin concerns. Full pooled safety data appear in the ORION-3 extension analysis on PubMed.

ORION-4: The Outcomes Trial That Will Define Clinical Utility

ORION-4 is the key cardiovascular outcomes trial for inclisiran. It enrolled approximately 15,000 adults aged 55 or older with established atherosclerotic cardiovascular disease across sites in the United Kingdom. The primary endpoint is a four-component composite: coronary heart disease death, myocardial infarction, fatal or non-fatal stroke, and urgent coronary revascularization. Enrollment completed in 2021 and primary completion is expected in 2026.

Why Outcomes Data Matter More for Off-Label Questions

LDL-C is a validated surrogate endpoint accepted by the FDA for drug approval in this drug class, backed by Mendelian randomization studies and the cholesterol treatment trialists' meta-analysis of more than 170,000 patients showing approximately 22% reduction in major vascular events per 1 mmol/L (roughly 38.7 mg/dL) LDL-C reduction. That meta-analysis is available through The Lancet.

For broader off-label use, however, payors and many clinicians want direct evidence of MACE reduction rather than relying entirely on surrogate extrapolation. ORION-4 will either confirm or complicate the linear LDL-outcome relationship in this specific drug class.

Interim Cardiovascular Signal From Pooled ORION Data

A pre-specified pooled analysis of ORION-9, ORION-10, and ORION-11 examined adjudicated cardiovascular events as an exploratory endpoint. Published in the Journal of the American College of Cardiology (available via PubMed), the analysis found a numeric 24% reduction in MACE with inclisiran vs. Placebo (odds ratio 0.76; 95% CI 0.58 to 1.01), though the combined trial set was not powered to achieve statistical significance for this endpoint. This finding supports biological plausibility but cannot replace ORION-4.

Guideline Positioning for Inclisiran and Implications for Off-Label Use

Understanding where guidelines place inclisiran clarifies the boundary between on-label and off-label prescribing.

ACC/AHA 2022 Cholesterol Guideline Update

The 2022 ACC/AHA focused update on nonstatin therapies identifies PCSK9 inhibitors (monoclonal antibodies evolocumab and alirocumab) as Class I, Level A evidence for very-high-risk ASCVD patients with LDL-C of 70 mg/dL or above on maximally tolerated therapy. Inclisiran carries a Class IIb recommendation in the same update, reflecting the absence of a dedicated outcomes trial at the time of writing. The guideline text states: "Inclisiran may be considered in very high-risk patients who require additional LDL-C lowering." The full guideline text is published in the Journal of the American College of Cardiology.

This Class IIb designation is consequential for off-label discussions. The approved ASCVD indication on the label maps closely to "very-high-risk" patients as defined by ACC/AHA. Prescribing inclisiran to lower-risk patients (for example, those who have not had an ASCVD event) represents a step further from guideline support than from FDA labeling alone.

ESC/EAS 2019 Dyslipidaemia Guidelines

The European Society of Cardiology and European Atherosclerosis Society 2019 guidelines recommend a PCSK9 inhibitor for very-high-risk patients failing statin plus ezetimibe combination therapy, with an LDL-C target of <55 mg/dL (Class I, Level A). Inclisiran was still in late trials when these guidelines were written and is not named specifically, but the 2022 ESC guideline update positions inclisiran alongside monoclonal antibody PCSK9 inhibitors for very-high-risk patients. Published through European Heart Journal via Oxford Academic.

Endocrine Society and AACE Positions

Neither the Endocrine Society nor AACE has published a position statement specific to inclisiran that differs materially from the ACC/AHA Class IIb placement. The AACE 2022 lipid guidelines endorse PCSK9 inhibitors broadly for very-high-risk patients and note that inclisiran "offers a twice-yearly dosing advantage that may improve adherence" without separately grading the siRNA class from the monoclonal antibody class. The AACE guideline is available at aace.com.

Mechanism of Action: Why Twice-Yearly Dosing Is Possible

Inclisiran works through RNA interference, a mechanistic difference from monoclonal antibody PCSK9 inhibitors such as evolocumab and alirocumab, which require subcutaneous injections every two or four weeks.

PCSK9 siRNA vs. Monoclonal Antibody PCSK9 Inhibitors

Inclisiran is a synthetic small interfering RNA conjugated to triantennary N-acetylgalactosamine (GalNAc) ligands that direct the molecule selectively to hepatocytes via asialoglycoprotein receptors. Once inside the hepatocyte, inclisiran is incorporated into the RNA-induced silencing complex (RISC), which then cleaves PCSK9 mRNA before it can be translated into protein. The result is a sustained suppression of PCSK9 protein production lasting approximately six months from a single injection.

Monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab) instead bind circulating PCSK9 protein extracellularly. Their half-lives of roughly 11 to 20 days necessitate every-two-week or monthly dosing. The mechanistic distinction does not appear to translate into meaningfully different LDL-C lowering at the hepatocyte level: both approaches reduce PCSK9 activity and allow more LDL receptors to recycle to the hepatocyte surface, clearing LDL particles from plasma.

Clinical Relevance of the Dosing Schedule

Adherence to cardioprotective medications declines steeply over 12 months in real-world settings. A 2020 analysis in JAMA Cardiology (PubMed) found that only 40 to 50% of patients prescribed a PCSK9 monoclonal antibody remained adherent at one year. A twice-yearly injection administered in a clinical setting removes the self-injection barrier and creates a built-in touchpoint for cardiovascular risk management. This adherence argument is frequently cited when clinicians consider inclisiran for patients who have struggled with biweekly injection regimens, even though no head-to-head adherence trial between inclisiran and evolocumab or alirocumab has been completed.

Applying GRADE to Off-Label Inclisiran for ASCVD Secondary Prevention

GRADE (Grading of Recommendations Assessment, Development and Evaluation) provides a structured way to assess the quality of evidence and strength of recommendation independently. Applying GRADE to the specific off-label use of inclisiran in ASCVD secondary prevention patients who fall outside strict FDA label criteria:

Surrogate Endpoint (LDL-C Reduction)

• Evidence quality: Moderate. Multiple large RCTs with consistent effect sizes and low risk of bias demonstrate 49 to 52% LDL-C reductions. Downgraded one level from High because the populations studied (ORION-10, ORION-11) overlap significantly with, but do not perfectly match, all proposed off-label patient groups.
• Strength of recommendation: Conditional (weak). Benefits likely outweigh risks for patients with documented ASCVD who cannot achieve LDL-C targets on statins plus ezetimibe, but the guideline classification is IIb pending outcomes data.

Hard Cardiovascular Outcomes (MACE)

• Evidence quality: Low. The pooled ORION MACE analysis (OR 0.76) is exploratory and underpowered. ORION-4 data have not yet reported. Mendelian randomization data and statin/ezetimibe extrapolation support plausibility, but plausibility is not the same as direct evidence.
• Strength of recommendation: Insufficient to make a strong recommendation for off-label indications not covered by existing ASCVD labeling until ORION-4 reports.

Practical Prescribing Considerations for Off-Label Requests

Clinicians and patients asking about inclisiran for ASCVD secondary prevention outside the strict label criteria should consider several practical factors before prescribing.

Prior Authorization and Payor Coverage

In the United States, most commercial payors and Medicare Part B require documentation of a prior ASCVD event and failure of statin plus ezetimibe before approving inclisiran. The drug's list price exceeds $3,500 per dose, making out-of-pocket cost prohibitive without authorization. Off-label use is less likely to receive approval, and appeals typically require detailed clinical documentation including LDL-C values on prior therapies and the reason for each failed agent.

Contraindications and Drug Interactions

Inclisiran has no clinically significant drug-drug interactions identified in phase 3 trials. It is not metabolized by cytochrome P450 enzymes. The only absolute contraindication is known hypersensitivity to inclisiran or any excipient. Pregnancy is listed as a warning due to the absence of human data; animal studies showed no teratogenicity at clinically relevant exposures, but this remains an area requiring caution.

Monitoring After Initiation

The FDA label does not require routine liver function monitoring. Standard lipid panel at 4 to 12 weeks after the third dose (the first steady-state dose at month 3) confirms therapeutic response. An LDL-C response below 30% from baseline warrants evaluation of adherence, injection technique, and whether a higher-potency baseline statin could further reduce the residual LDL-C burden.

Combination With Ezetimibe

Current ACC/AHA guidelines recommend adding ezetimibe before a PCSK9 inhibitor in most patients due to cost-effectiveness modeling. Ezetimibe reduces LDL-C by an additional 18 to 24% and costs under $10/month generic. For off-label use, the case for inclisiran becomes substantially stronger after documenting failure of statin plus ezetimibe, both because the clinical rationale is clearer and because payor approval is more achievable.

What the Evidence Does Not Yet Show

Three gaps in the current evidence base are relevant to any clinician or patient considering off-label inclisiran for ASCVD secondary prevention.

First, there are no data from dedicated trials in statin-intolerant patients using inclisiran as monotherapy. ORION-10 and ORION-11 required background statin therapy for eligibility. Extending conclusions to monotherapy use requires extrapolation, and monoclonal antibody PCSK9 inhibitors (not inclisiran) have the most strong data in that specific scenario from the GAUSS-3 trial (evolocumab, N=511, published in JAMA).

Second, no head-to-head trial compares inclisiran directly to evolocumab or alirocumab on cardiovascular outcomes. PCSK9 siRNA and PCSK9 monoclonal antibody approaches are treated as mechanistically interchangeable in many guidelines, but that assumption rests on the LDL-hypothesis extrapolation rather than direct comparative data.

Third, inclisiran has not been studied in homozygous familial hypercholesterolemia (HoFH). The FDA label explicitly covers only HeFH. Using inclisiran in HoFH represents a distinct off-label use with additional scientific uncertainty, since patients with two non-functional LDLR alleles have limited capacity to upregulate LDL receptor expression regardless of PCSK9 suppression.

Summary of GRADE Evidence Table for Off-Label ASCVD Secondary Prevention

| Population | Outcome | Quality of Evidence | Effect Estimate | |---|---|---|---| | ASCVD on max-tolerated statin (ORION-10) | LDL-C reduction at 510 days | Moderate | 52.3% reduction vs. Placebo | | ASCVD risk equivalents (ORION-11 subset) | LDL-C reduction at 510 days | Low-Moderate | ~49% reduction (subgroup) | | Pooled ASCVD (ORION-9, 10, 11) | Adjudicated MACE (exploratory) | Low | OR 0.76 (95% CI 0.58 to 1.01) | | Broad secondary prevention (ORION-4) | Primary MACE composite | Pending | Trial ongoing, expected 2026 |